INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Enzymotec Ltd.

Glancy Binkow & Goldberg LLP reminds investors of Enzymotec Ltd. (“Enzymotec” or the “Company”) (NASDAQ:ENZY) that all purchasers of the Company’s securities pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with the Company’s initial public offering on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, inclusive (the “Class Period”), have until November 4, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.

Enzymotec develops, manufactures and markets bio-active lipid ingredients used in the production of various nutritional products. The Company’s primary source of revenue is through its baby formula business, including the popular InFat line of products. The Complaint alleges that the Registration Statement and Prospectus contained materially false and misleading statements and omitted material information, and that defendants misrepresented and/or failed to disclose throughout the Class Period that:

• Enzymotec’s Chinese business was subject to material and readily identifiable compliance regulations from the Chinese government.
• The Company’s baby formula business in China was jeopardized and subject to increased volatility and decreased revenues.
• The Company’s joint venture with AarhusKarlshamn AB, which marketed the popular InFat product, was crumbling and subjected the Company to liability and decreased revenues.
• Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On May 14, 2014, the Company disclosed for the first time that “Chinese regulations require infant formula manufacturers to make certain changes to their production chain,” and as a result the Company’s revenues were lower. On this news, shares of the Company's stock declined $6.48 per share, or over 32%, to close at $13.75 per share on May 14, 2014, on unusually heavy trading volume

Then, on August 5, 2014, the Company further disclosed the increased impact of the Chinese regulations on its sales of infant formula, and announced financial results that were significantly lower than the prior year in almost all respects. As a result of this news, Enzymotec shares declined $5.85 per share, or nearly 40%, to close on August 5, 2014, at $9.11 per share, on volume of more than 1 million shares.

If you are a member of the Class described above, you may move the Court no later than November 4, 2014, to serve as lead plaintiff; however, you must meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, or Casey Sadler, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, at (310) 201-9150, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.